acpd

(1S,3R)-ACPD is an agonist for both group I and II metabotropic glutamate (mGlu) receptors.

NPEC-caged-(1S,3R)-ACPD is an agonist for group I and II mGlu receptors.

trans-ACPD ((±)-trans-ACPD) is an equimolecular mixture of (1S, 3R)- and (1R, 3S)-ACPD. trans-ACPD is a selective agonist of the mGluR (metabotropic glutamate receptor); active at the group I/II mGlu receptors (EC50: 2/15/23/800 μM, mGluR2/1/5/4).

CACPD2011a-0001278239 is a β2AR hybrid agonist with high affinity binding to both the wild-type and T164I β2AR variants. It exhibits neither cytotoxicity nor mutagenicity, making it suitable for asthma research.

3,5-Diiodothyropropionic acid (C082182) is a thyroid hormone analog. It induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (Ka: 2.40/M and 4.06/M for TRα1 and TRβ1).

DMAC-PDB is a cleavable linker vital in ADC synthesis. DMAC-PDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

PROTAC PD-L1 degrader-2, an orally administered compound, targets HPK1 and boosts the efficacy of PD-L1 antibody therapy.

PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.

PROTACPDE4 degrader-1 (Compound 9m) is an orally active, selective PDEC4 PROTAC degrader with a DC50 of 41.98 μM. It effectively inhibits the secretion of pro-inflammatory cytokines, such as TNF-α and IL-6, and significantly reduces pulmonary inflammation in a mouse model of LPS-induced acute lung injury (ALI).

PROTACPDIA1 degrader 1 (Compound H4) is a PDIA1 PROTAC degrader with a DC50 value of 29.71 μM. It exhibits potent anticancer activity and significantly inhibits the proliferation of cancer cells.

PROTAC PD-1/PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1/PD-L1 PROTAC that effectively inhibits the PD-1/PD-L1 interaction with an IC50 of 39.2 nM. It restores the suppressed immune response in a co-culture model of Hep3B/OS-8/hPD-L1 cells and CD3 T cells and moderately decreases PD-L1 protein levels through a lysosome-dependent mechanism.

(Rac)-PD0299685 is a potent voltage-dependent calcium channel inhibitor for the study of retina-related diseases.

IQDMA is an inhibitor of the transcription factor STAT5.

Ebracteolata cpd B (TN3909, CAS 83459-37-4) is a natural product utilized in life sciences research.

Ibotenic acid (RS-42358-197) has agonist activity at both the NMDA and trans-ACPD or metabotropic quisqualate receptors.